Apr 14, 2011
By:
Erik Greb
FDA recently published guidance for preventing the cross-contamination of finished pharmaceuticals and active pharmaceutical ingredients with nonpenicillin beta-lactam antibiotics.
|
Apr 7, 2011
By:
Erik Greb
Johnson & Johnson has instituted a new structure for its Consumer Group according to a Reuters report.
|
|
Regulators question whether particles that they can't see hurt patients.
Apr 2, 2011
By:
Erik Greb
Regulators question whether particles that they can't see hurt patients.
|
Mar 31, 2011
By:
Erik Greb
On Mar. 23, 2011, sanofi-aventis offered $7 billion in notes to fund its acquisition of Genzyme. The notes are offered in six tranches scheduled to come due between 2012 and 2021, and the interest rates range from 0.05% to 4%.
|
Mar 24, 2011
By:
Erik Greb
Pfizer is considering divesting some of its businesses to maximize their value, according to remarks made by Mikael Dolsten, Pfizer's president of worldwide research and development, at a Barclays Capital investor conference last Thursday.
|
Mar 17, 2011
By:
Erik Greb
Last Thursday, FDA filed a consent decree of permanent injunction against McNeil, a subsidiary of Johnson & Johnson, for failing to comply with current good manufacturing practice requirements. The action prevents McNeil from manufacturing and distributing drugs from its Fort Washington, Pennsylvania, facility until FDA determines that its operations comply with the law.
|
Mar 17, 2011
By:
Erik Greb
Last Tuesday, the US Senate approved the "America Invents Act," which is intended to reform the nation ’s patent system. If it becomes law, the bill will establish a first-to-file system by defining an invention ’s effective filing date as the actual filing date of the patent or patent application.
|
Mar 16, 2011
By:
Erik Greb
Growing interest in continuous drug manufacturing has brought greater attention to in-line blending, a process that the petroleum and fine-chemicals industries have used for decades.
|
Mar 14, 2011
By:
Erik Greb
FDA and J&J signed a consent decree of permanent injunction that prevents the company from manufacturing or shipping drugs from its Fort Washington facility until it complies with current good manufacturing practice requirements.
|
|
